Contraindications
- Pregnancy or possible pregnancy
Dosing: Adult
- Hypertension: 5 to 10 mg once daily after breakfast; up to 20 mg once daily; severe hypertension 10 to 20 mg once daily
Dosing: Altered kidney function
Cilnidipine is a dihydropyridine calcium-channel blocker (L- and N-type) metabolized by CYP3A4 with no unchanged drug in urine. In patients with serum creatinine 1.5 to 3.1 mg/dL its levels were the same as with normal kidney function, and the Japanese insert sets no kidney dose change. It has no US FDA label.
Kidney function measure: Japanese kidney data are by serum creatinine (1.5 to 3.1 mg/dL); bands shown on creatinine clearance (CrCl) by judgment.
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 5 to 10 mg once daily after breakfast; up to 20 mg once daily (PMDA insert). Older adults: start 5 mg.
- CrCl 30–59 mL/min
- No kidney dose change in the Japanese insert. A 10 mg dose in patients with serum creatinine 1.5 to 3.1 mg/dL gave levels no different from normal kidney function, with no accumulation over 7 days (PMDA insert).
- CrCl 15–29 mL/min
- No kidney dose change in the Japanese insert. A 10 mg dose in patients with serum creatinine 1.5 to 3.1 mg/dL gave levels no different from normal kidney function, with no accumulation over 7 days (PMDA insert).
- CrCl <15 mL/min (not on dialysis)
- Not studied below the creatinine range tested (1.5 to 3.1 mg/dL). Hepatically cleared, so a change is not expected; titrate from 5 mg.
- Hemodialysis (intermittent)
- Not studied in dialysis (PMDA insert). Hepatically cleared; start low and titrate.
- Peritoneal dialysis
- Not studied.
- CRRT
- Not studied.
- Dialyzable? Not stated (99.3% protein-bound).
- Monitoring Blood pressure (avoid excessive lowering in older adults); liver tests if symptoms (hepatic dysfunction, jaundice); platelets (thrombocytopenia under 0.1%) (PMDA insert).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: PMDA (Japan) product information (June 2023). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- No pediatric trials (PMDA insert).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 10 mg, 20 mg
- Tablet: 5 mg
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list Cilnidipine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products5
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CildineCilnidipine | 10mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47574 | Dec 1, 2026 | |
CildineCilnidipine | 20mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines, Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY47575 | Dec 1, 2026 | |
Nulong 10Cilnidipine | 10 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49400 | May 22, 2030 | |
Nulong 20Cilnidipine | 20 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49401 | May 22, 2030 | |
Nulong 5Cilnidipine | 5 mg TabletAlu-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49399 | May 22, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Azole antifungals (itraconazole, miconazole), cimetidine, grapefruit juice | Adjust or monitor | Higher cilnidipine levels. | Monitor blood pressure; avoid grapefruit. |
| Rifampicin | Adjust or monitor | Lower cilnidipine levels. | Monitor blood pressure. |
| Digoxin | Adjust or monitor | Calcium-channel blockers can raise digoxin levels. | Watch for digoxin toxicity. |
| Other antihypertensives | Minor | Additive blood-pressure lowering. | Adjust doses. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Dizziness, headache
- Flushing, palpitations
- Edema
Serious
- Hepatic dysfunction, jaundice
- Thrombocytopenia
Monitoring parameters
- Blood pressure (avoid excessive lowering in older adults); liver tests if symptoms (hepatic dysfunction, jaundice); platelets (thrombocytopenia under 0.1%) (PMDA insert). Kidney
- Blood pressure
- Liver tests if symptoms
Pharmacokinetics
Key PK parameters
| Time to peak | About 2.5 to 2.8 hours |
|---|---|
| Half-life | About 7 hours single dose (5.2 hours on day 1 to 8.1 hours on day 7 with repeat dosing) |
| Half-life in kidney failure (ESKD) kidney | Unchanged at serum creatinine 1.5 to 3.1 mg/dL |
| Protein binding | 99.3% |
| Metabolism (CYP, transporters) | Mainly CYP3A4, some CYP2C19 |
| Renal excretion kidney | No unchanged drug in urine; metabolites 5.2% |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Pharmaceuticals and Medical Devices Agency (Japan). Cilnidipine tablets "SAWAI" package insert [PMDA (Japan) product information, June 2023; no US FDA label]. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987080906407
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Sawai Pharmaceutical Co., Ltd. (2023). Cilnidipine tablets 5 mg, 10 mg and 20 mg "SAWAI" [Japanese package insert, 1st edition, revised June 2023]. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. https://www.pmda.go.jp/PmdaSearch/bookSearch/01/04987080906407
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .